Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article (361)

Advertisement

Free access | 10.1172/JCI108886

H2O2 Release from Human Granulocytes during Phagocytosis: RELATIONSHIP TO SUPEROXIDE ANION FORMATION AND CELLULAR CATABOLISM OF H2O2: STUDIES WITH NORMAL AND CYTOCHALASIN B-TREATED CELLS

Richard K. Root and Julia A. Metcalf

Infectious Disease Section, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06510

Find articles by Root, R. in: PubMed | Google Scholar

Infectious Disease Section, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06510

Find articles by Metcalf, J. in: PubMed | Google Scholar

Published December 1, 1977 - More info

Published in Volume 60, Issue 6 on December 1, 1977
J Clin Invest. 1977;60(6):1266–1279. https://doi.org/10.1172/JCI108886.
© 1977 The American Society for Clinical Investigation
Published December 1, 1977 - Version history
View PDF
Abstract

Normal and cytochalasin B-treated human granulocytes have been studied to determine some of the interrelationships between phagocytosis-induced respiration and superoxide and hydrogen peroxide formation and release into the extracellular medium by intact cells. By using the scopoletin fluorescent assay to continuously monitor extracellular hydrogen peroxide concentrations during contact of cells with opsonized staphylococci, it was demonstrated that the superoxide scavengers ferricytochrome c and nitroblue tetrazolium significantly reduced the amount of H2O2 released with time from normal cells but did not abolish it. This inhibitory effect was reversed by the simultaneous addition of superoxide dismutase (SOD), whereas the addition of SOD alone increased the amount of detectable H2O2 in the medium. The addition of sodium azide markedly inhibited myeloperoxidase-H2O2-dependent protein iodination and more than doubled H2O2 release, including the residual amount remaining after exposure of the cells to ferricytochrome c, suggesting its origin from an intracellular pool shared by several pathways for H2O2 catabolism.

When cells were pretreated with cytochalasin B and opsonized bacteria added, reduced oxygen consumption was observed, but this was in parallel to a reduction in specific binding of organisms to the cells when compared to normal. Under the influence of inhibited phagosome formation by cytochalasin B, the cells released an increased amount of superoxide and peroxide into the extracellular medium relative to oxygen consumption, and all detectable peroxide release could be inhibited by the addition of ferricytochrome c. Decreased H2O2 production in the presence of this compound could not be ascribed to diminished bacterial binding, decreased oxidase activity, or increased H2O2 catabolism and was reversed by the simultaneous addition of SOD. Furthermore, SOD and ferricytochrome c had similar effects on another H2O2-dependent reaction, protein iodination, in both normal and cytochalasin B cells. When oxygen consumption, O2.−, and H2O2 release were compared in the presence of azide under identical incubation conditions, the molar relationships for normal cells were 1.00:0.34:0.51 and for cytochalasin B-treated cells 1.00:0.99:0.40, respectively. Nonopsonized, or opsonized but disrupted, bacteria did not stimulate any of these metabolic functions.

The results indicate that with normal cells approximately 50% of H2O2 released during phagocytosis is derived directly from O2.− by dismutation, the remainder appearing from an (intra)cellular source shared by azide-inhibitable heme enzymes. With cytochalasin B treatment the evidence is consistent with the derivation of all H2O2 from an O2.− precursor which is released from the cell surface. Furthermore, when activated by phagocytic particle binding, the neutrophil O2.− generating system appears to make more of this compound than can be accounted for by dismutation to H2O2. This establishes conditions for the direct participation of both compounds in the microbicidal and cytocidal activity of these cells.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1266
page 1266
icon of scanned page 1267
page 1267
icon of scanned page 1268
page 1268
icon of scanned page 1269
page 1269
icon of scanned page 1270
page 1270
icon of scanned page 1271
page 1271
icon of scanned page 1272
page 1272
icon of scanned page 1273
page 1273
icon of scanned page 1274
page 1274
icon of scanned page 1275
page 1275
icon of scanned page 1276
page 1276
icon of scanned page 1277
page 1277
icon of scanned page 1278
page 1278
icon of scanned page 1279
page 1279
Version history
  • Version 1 (December 1, 1977): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article (361)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts